The company behind Ozempic cannot be taken over, because Novo Nordisk has been controlled since the 1920s by a Danish foundation whose charter obliges it to keep control, and the weight-loss boom has quietly made that foundation the largest charitable fund on Earth, ahead of the Gates Foundation

Novo Nordisk is, depending on the week, the most valuable company in Europe or close to it — the maker of Ozempic and Wegovy, the drugs that turned appetite itself into a hundred-billion-dollar market.

Any normal company that valuable would live under permanent siege: activist investors, takeover rumors, private equity circling. Novo Nordisk lives under none of it, because Novo Nordisk cannot be bought.

Not “would be expensive to buy.” Cannot. The controlling shares are legally forbidden from ever being sold, by a charter written when insulin was the miracle drug of the moment.

The charity that owns the company

The controlling owner of Novo Nordisk is the Novo Nordisk Foundation in Copenhagen, whose roots run back to the 1920s, when the Danish pioneers of insulin production placed their enterprises under foundation ownership; the modern foundation was consolidated from those original bodies.

The structure is a Danish specialty called an enterprise foundation — a self-owning institution with no shareholders and no members, existing only to carry out its charter. And the charter commits it to two jobs: maintain the commercial activities of the Novo companies, and give the resulting wealth away to science and society.

The control is engineered to be permanent. Novo Nordisk has two share classes; the foundation, through its investment arm Novo Holdings, owns all of the ten-vote A-shares — never traded, never tradeable — giving it roughly three-quarters of the votes with a much smaller slice of the economics. A hostile acquirer could buy every B-share on the exchange and still lose every vote that matters. There is no premium at which the company changes hands, because there is no seller.

Then came Ozempic

For most of a century this was a Danish curiosity. Then the company the foundation is chained to invented the most commercially explosive medicines of the age.

GLP-1 drugs — Ozempic, Wegovy and their successors — sent Novo Nordisk’s value vertical, and since the foundation cannot sell, the windfall simply piled up inside it. By the most recent accounting, the foundation’s assets stand at more than $110 billion, and at the stock’s 2023-24 peak the figure approached $150 billion.

That makes the Novo Nordisk Foundation the wealthiest charitable foundation on Earth — larger than the Bill & Melinda Gates Foundation, larger, at its peak, than Gates and the Wellcome Trust combined. The world’s biggest philanthropy is not in Seattle. It is in Copenhagen, and almost nobody outside Denmark can name it.

The money is moving accordingly. The foundation’s grantmaking has more than doubled since 2018, past a billion dollars a year; it opened 2026 with its largest commitment ever, up to $860 million to a Danish bioinnovation institute; and it has begun co-funding global health programs alongside Gates and Wellcome — stepping onto the stage just as government aid budgets shrink and the Gates Foundation announces its own wind-down by 2045.

The honest asterisks

The comparison with Gates needs its footnotes, and the foundation’s own leadership supplies them.

An enterprise foundation’s wealth is mostly locked in the company it exists to protect — only about a fifth of the assets are actually accessible for philanthropy, and Gates still gives away several times more per year. Biggest by assets is not biggest by giving; the foundation’s own CEO calls the comparison “not quite comparable.” The asset number also breathes with the share price, and Novo’s stock has slumped from its peak as GLP-1 competition intensified — the largest-fund crown is real but not guaranteed.

And critics exist on both flanks: pricing campaigners note the fortune rests partly on decades of expensive insulin and now expensive weight-loss drugs, while philanthropy scholars worry about unelected mega-funders steering global health. A charity that owns a drug company sits, permanently, on both sides of several arguments.

What the arrangement actually buys

Strip the numbers away and the design is the interesting part.

The 1920s founders solved a problem every successful company eventually faces — who will own this after us, and what will they do with it — by making the answer nobody, forever. No heirs to feud, no acquirer to strip it, no quarterly activist demanding the research budget. Novo Nordisk spent decades on patient, unfashionable diabetes science partly because no owner could force it to do anything else, and when that science produced the jackpot, the jackpot flowed, by charter, into laboratories instead of yachts.

It is the same trick the Wallenbergs run in Sweden and the Tata Trusts in India: a fortune designed so that keeping it and giving it away are the same act. Denmark just holds the current record. The most coveted company in Europe has no owner to tempt, no price to name, and a hundred-year-old document in Copenhagen quietly converting the world’s appetite into the world’s largest charity.